In addition to lymphoma and leukemia, CAR-T cells have also made great progress in treatment of MM.278,438–446 Idecabtagene vicleucel (ide-cel) and ciltacabtagene autoleucel (cilta-cel) have already been approved by the FDA based on responses and safety demonstrated in the KarMMa and CARTITUDE-1 trials.439,440,442 Meanwhile, more companies have launched CAR-T cell products for MM, such as orva-cel, P-BCMA-101.443,444,446–449 CAR-T cell products against the new target, GPRC5D, have also been developed without delay. Here, GPRC5D is linked to Miyoshi myopathy.